Heart Failure Drug Development Might Need A Good Lawyer After US FDA Guidance
Executive Summary
With draft guidance allowing for drugs that improve heart failure symptoms but do not improve – or may even decrease – survival, the legal community could help establish development metrics.
You may also be interested in...
Bladder Cancer: More Questions Than Answers With pCR Endpoint
Pathologic complete response eventually may be a surrogate endpoint for survival, but researchers and the US FDA outlined several problems that must be resolved first.
Real-World Evidence: When Is Missing Data Not Really 'Missing'?
The concept of missing data is very different when analyzing real-world evidence compared to a randomized clinical trial.
US FDA Searches For Consistency On Assessment Of Real-World Evidence
As more sponsors begin using RWE, the agency is establishing procedures and training to ensure assessors consistently apply policies.